Innocan Pharma CORP F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
Innocan Pharma Corporation files an F-1 registration statement for an initial public offering of units to advance its LPT-CBD drug delivery platform and expand its consumer wellness segment.
Innocan Pharma Corporation filed Amendment No. 7 to its F-1 registration statement, primarily updating legal exhibits and detailing past unregistered securities sales ahead of a proposed public offering.
Innocan Pharma Corporation is seeking to raise approximately $10.89 million in an initial public offering on the NYSE American to advance its preclinical LPT-CBD drug delivery platform and expand its consumer wellness segment.
Innocan Pharma Corporation is launching an initial public offering of 2.35 million units on the NYSE American to raise approximately $10.89 million, primarily to advance its preclinical CBD-loaded liposome platform for chronic pain management.
Innocan Pharma Corporation filed Amendment No. 4 to its F-1 Registration Statement to enable automatic effectiveness and update an exhibit, without modifying its prospectus.
Innocan Pharma Corporation filed an F-1/A registration statement for an initial public offering of 1,088,157 units on Nasdaq to fund its LPT-CBD chronic pain management drug development and expand its consumer wellness segment.
Innocan Pharma Corporation filed an amended F-1 registration statement for its initial public offering on Nasdaq, outlining its dual focus on advanced cannabinoid pharmaceuticals for chronic pain and a growing consumer wellness segment, while detailing financial performance and future development plans.
Innocan Pharma Corporation is launching an initial public offering of units to list on Nasdaq, aiming to raise capital for its preclinical LPT-CBD drug development for chronic pain and expand its consumer wellness products.
Innocan Pharma Corporation is pursuing a Nasdaq listing and an initial public offering to fund its innovative LPT-CBD drug development for chronic pain and expand its consumer wellness segment.